NCT07222995 Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
| NCT ID | NCT07222995 |
| Status | Recruiting |
| Phase | — |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Condition | Skin Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,900 participants |
| Start Date | 2025-10-10 |
| Primary Completion | 2030-10-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,900 participants in total. It began in 2025-10-10 with a primary completion date of 2030-10-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine how different messages about risk of skin cancer can impact the uptake of skin cancer prevention activities.
Eligibility Criteria
Inclusion Criteria: * Be a patient of any race or ethnicity attending one of the six Tampa Family Health Centers. * Be 18 years of age or older. * Self-report skin cancer risk behaviors within the past 12 months, including: Intentional sun exposure (e.g., outdoor or indoor tanning) or unintentional sun exposure leading to sunburn. * Be willing to complete a baseline questionnaire and provide a saliva sample for MC1R genotyping. * Be able to provide informed consent (written or electronic). * Prefer English or Spanish for communication and study materials. Exclusion Criteria: * Do not report any skin cancer risk behaviors (i.e., no tanning or sunburning in the past 12 months). * Are unwilling or unable to complete the baseline assessment or return the saliva kit. * Decline to provide informed consent. * Are under 18 years of age.
Contact & Investigator
Peter Kanetsky, PhD, MPH
PRINCIPAL INVESTIGATOR
Moffitt Cancer Center
Frequently Asked Questions
Who can join the NCT07222995 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Skin Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07222995 currently recruiting?
Yes, NCT07222995 is actively recruiting participants. Contact the research team at Rania.Abdulla@moffitt.org for enrollment information.
Where is the NCT07222995 trial being conducted?
This trial is being conducted at Tampa, United States, New York, United States.
Who is sponsoring the NCT07222995 clinical trial?
NCT07222995 is sponsored by H. Lee Moffitt Cancer Center and Research Institute. The principal investigator is Peter Kanetsky, PhD, MPH at Moffitt Cancer Center. The trial plans to enroll 2,900 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.